insights_auto
Why is AXGN up 31,47%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
49,25 $
arrow_upward
+31,47%(+11,79) 1D
49,40 $
arrow_upward
+0,30% (+0,15)bedtimeAfter hours
Closed: 28 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
45,44 $
High
49,97 $
Low
43,50 $
Mkt. cap
2,88 մլրդ
Avg. vol.
1,41 մլն
Volume
0,00
52-wk high
52,91 $
52-wk low
18,46 $
EPS
-0,68 $
Beta
1,17
Shares outstanding
58,67 մլն
No. of employees
622
Open
45,44 $
High
49,97 $
Low
43,50 $
Mkt. cap
2,88 մլրդ
Avg. vol.
1,41 մլն
Volume
0,00
52-wk high
52,91 $
52-wk low
18,46 $
EPS
-0,68 $
Beta
1,17
Shares outstanding
58,67 մլն
No. of employees
622
News stories
From web sources and news partners
TradingView
·
10 ժամ առաջ
Axogen, Inc. Stock 12‑Month Price Target Raised to $54, Implies 44% Upside
Investing.com
·
11 ժամ առաջ
Mizuho raises AxoGen stock price target to $65 on growth outlook
The Globe and Mail
·
13 ժամ առաջ
Axogen (AXGN) Q3 2026 Earnings Call Transcript
Benzinga
·
15 ժամ առաջ
12 Health Care Stocks Moving In Wednesday's Intraday Session
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Ֆլորիդա, Միացյալ Նահանգներ
Sector-
Websiteaxogeninc.com